bactox
laboratoire innotech international s.a.s. - amoksicilinas - milteliai geriamajam tirpalui - 250 mg/5 ml; 500 mg; 125 mg/5 ml - amoxicillin
fluorouracil accord
accord healthcare b.v. - fluorouracilas - injekcinis ar infuzinis tirpalas - 50 mg/ml - fluorouracil
fosinopril actavis
teva b.v. - fosinoprilio natrio druska - tabletės - 10 mg; 5 mg; 20 mg - fosinopril
fosinopril hct actavis
teva b.v. - fosinoprilio natrio druska/hidrochlorotiazidas - tabletės - 20 mg/12,5 mg - fosinopril and diuretics
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 500 mg - cyclophosphamide
cyclophosphamide accord
accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 1000 mg - cyclophosphamide
imprida hct
novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hipertenzija - angiotenzino ii antagonistai, paprastas, angiotenzino ii antagonistai, deriniai - pirminės arterinės hipertenzijos gydymas kaip pakaitinė terapija suaugusiems pacientams, kurių kraujospūdžio tinkamai kontroliuojama į derinį amlodipino, valsartano ir hidrochlorotiazido (hct), paimti tris vienkomponenčiai preparatai arba kartu su šiuolaikiška dviejų ir vieno komponento sudėties.
puri-nethol
aspen pharma trading limited - merkaptopurino monohidratas - tabletės - 50 mg - mercaptopurine
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitinė, lėtinė, b-ląstelė - antinavikiniai vaistai - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
imuran
aspen pharma trading limited - azatioprinas - plėvele dengtos tabletės - 50 mg - azathioprine